BeOne Medicines Ltd.
NASDAQ:ONC · NASDAQ Global Market
+$6.48 today
Vol 0.32M · Avg 0.24M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6.6%
avg -25.2%
ROIC
4.7%
avg -30.0%
ROA
3.5%
avg -25.1%
Analysis
ROE is currently the strongest return metric at 6.6% versus its period average of -25.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Xiaodong Wang | Co-Chairman of Scientific Advisory Board, Non-Executive Director & Co-Founder | $4.25M | — | 63 | $1.71M | 1.60% |
John V. Oyler | Co-Founder, Executive Chairman & Chief Executive Officer | $2.94M | — | 58 | $344,669.00 | 0.32% |
Wang Lai | President and Global Head of Research & Development | $1.32M | — | 48 | $1.71M | 1.60% |
Aaron Rosenberg | Chief Financial Officer | $1.27M | — | 49 | $397,891.00 | 0.37% |
Chan Lee | General Counsel, Senior VP & Corporate Secretary | $1.26M | — | 58 | $346,554.00 | 0.32% |
Eleanor Duff | Senior Vice President & Head of Corporate Communications | — | — | — | — | — |
Mark Lanasa | Senior Vice President & Chief Medical Officer for Solid Tumors | — | — | — | — | — |
Graham Hardiman | Global Head of Human Resources | — | — | — | — | — |
Titus Ball | Vice President & Chief Accounting Officer | — | — | 52 | $99,645.00 | 0.09% |
Marcello Damiani | Chief Technology Officer | — | — | 56 | — | — |
Liza Heapes | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
96
$67.15M
Net Sentiment
$67.15M
Net selling
Most Active
OYLER JOHN
35 transactions
1–10 of 96
Analysis
Insiders reported 0 buys worth $0.00 and 96 sells worth $67.15M over the last 12 months. That adds up to net selling of $67.15M. OYLER JOHN was the most active insider with 35 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +163.5% | +33.8% (13yr)15 analysts |
| Net Income | N/A | N/A | N/A | N/A15 analysts |
| EBIT | N/A | N/A | N/A | N/A15 analysts |
Analysis
Recent growth has been strongest in Revenue at +163.5% over three years. Forward estimates point to Revenue at +33.8% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Humana Inc.
NYSE:HUM
$43.09B
Agilent Technologies, Inc.
NYSE:A
$35.98B
Natera, Inc.
NASDAQ:NTRA
$32.78B
Alcon Inc.
NYSE:ALC
$31.57B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$28.04B
IQVIA Holdings Inc.
NYSE:IQV
$27.96B
ResMed Inc.
NYSE:RMD
$27.25B
Koninklijke Philips N.V.
NYSE:PHG
$26.04B
Mettler-Toledo International Inc.
NYSE:MTD
$23.16B
Insmed Incorporated
NASDAQ:INSM
$20.65B
Who manages ONC?
BeOne Medicines Ltd. (ONC) lists 11 active executives. The top listed executive is Aaron Rosenberg, Chief Financial Officer.
Are ONC insiders buying or selling?
Recent insider activity shows net selling of $41.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.